Type II alveolar epithelial cells and lung microvascular endothelium

Type II alveolar epithelial cells (ATII) and lung microvascular endothelial cells (LMVECs) are the primary cellular components of the alveolar-capillary barrier, which is essential for efficient gas exchange in the lungs. ATII cells are specialized epithelial cells that synthesize and secrete pulmonary surfactant to reduce surface tension and prevent alveolar collapse [1]. They also function as progenitor cells, proliferating and differentiating into Type I alveolar cells to restore the epithelial lining following lung injury [2]. LMVECs form the inner lining of the pulmonary capillaries and play a critical role in regulating vascular permeability and the recruitment of inflammatory cells [3]. The coordinated function of these two cell types maintains the dry environment of the alveoli and facilitates the diffusion of oxygen and carbon dioxide. Dysfunction or damage to this barrier is a hallmark of severe respiratory conditions, including Acute Respiratory Distress Syndrome (ARDS) and Idiopathic Pulmonary Fibrosis (IPF) [4]. While these cells are the site of action for various pharmacological interventions, such as exogenous surfactants and anti-fibrotic agents, they represent a complex tissue system rather than a single molecular target.

Other names

Alveolar type II cellsAT2 cellsPulmonary microvascular endothelial cellsPMVECsAlveolar-capillary barrierBlood-air barrier

Not applicable as this entry describes a combination of cell types rather than a single molecular target.